[ad_1]
Ildong Pharm (CEO Yoon Woong-seop) announced on August 1 that he was going to launch "Telos Top Plus", a combination drug for hypertension and hyperlipemia .
This product is a combination of three drugs, including the series of angiotensin II receptor blockers (ARBs) telmisartan, calcium channel blocker (CCB) amlodipine, and the series of hypolipidemic statins suvastatin [19659004] Ildong Pharma conducts clinical trials for Telos top plus in hypertensive patients with hyperlipidemia from November 2015 to June 2017 by telmisartan, amlodipine, rosuvastatin They have shown superiority in the control of 39, hyperlipidemia and hypertension, respectively, compared with the diet of two drugs with telmisartan and amlodipine, and the diet of two drugs with telmisartan and rosuvastatin, respectively.
Telos Topplus recommends that patients with essential hypertension and hypercholesterolemia be treated with telmisartan / amlodipine and rosuvastatin,
The release dosage unit is based on telmisartan / amlodipine / rosuvastatin = 40/5 / 5mg ▲ 40/5 / 10mg ▲
Ildong Pharmaceutical, a representative of cardiovascular risk factors, arterial hypertension and hyperlipidemia, is highly correlated and presents a strong proportion of co-occurrence, "and"
In the case of hypertension and hyperlipidemia, it is said that "in addition to the one-component treatment, it is possible to use the top telos, "We have added a combination of two drugs, including Telos Top Plus, and Triple Plus, to increase the product line so that not only individual treatments for diseases, but also simultaneous treatment are possible." [19659002] Ildong Pharm is a strategy to induce market penetration and marketing synergy by promoting a broad range of products including cardiovascular therapeutics for various series and ingredients, combined with convenience of use and use improved
Source link
